Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
about
A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokiVariation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicityPhase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.Taxanes in the treatment of breast cancer: a prodigy comes of age.Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy(-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma.Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cellsChemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience.Recent advances in the systemic therapy of breast cancer.Clinical trials in the era of personalized oncology.Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study.A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors.Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases.Taxanes: a new class of antitumor agents.Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma.Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions.Growth inhibitory effects of paclitaxel on human epithelioid sarcoma in vitro: heterogeneity of response and the multidrug resistance phenotype.Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients.A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group.Concurrent Paclitaxel and Radiation Therapy for Solid Tumors.Apoptosis Reversal Promotes Cancer Stem Cell-Like Cell Formation.Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.Therapeutic options for metastatic breast cancer
P2860
Q28344321-5215FF76-D6B4-4026-B096-822D59409464Q28366611-682CAD93-771D-4F87-861B-F1C5D82CC3B6Q33367028-FEF8DF0E-21D8-4472-80B7-118BA02FDA66Q33501861-84C361F8-E5E4-4C7B-8176-4AC8E4471DDFQ33539951-32731914-55ED-485F-BE2E-A586A6EFEA71Q33737986-ED3C4CEA-8E55-48EF-A122-1E424A43A16BQ33892907-A1CAB2A6-B34B-4396-B56B-BEB0659B0CCFQ34096921-3F09327E-FD23-44AD-BB62-AC277A3B487BQ34182224-D62629BC-1FCF-42E8-BF50-64D313C9CBD6Q34273153-093FAFF9-F4DA-4815-A03E-CA17D2075ACBQ35052282-0FCD273E-C22B-440C-9AC1-CC44FDD6066BQ35555963-DA86EE50-F329-472A-BEBF-22EAE8FD2176Q35633680-DA745674-4ED6-4D4B-A746-571C02951817Q36074388-CB7353C2-25E3-42F3-82B2-F07285B51EEEQ36136477-77202888-B6E7-46EE-9895-252F69E26DABQ36885663-AF18BFC9-C29C-4E63-8D41-C7C4C24215E7Q37476245-516A2178-8C4A-4500-B494-B883ADB0D9DBQ37875412-16BC586B-03A7-44BF-B1D5-7F4FBED09ABCQ40247703-E42F66CE-76A5-4D6E-B12F-CE1D0F80F01DQ40456125-345F4F6B-E63D-4C53-8EC1-46DCD9623DB5Q40619568-AA07B1C2-A153-4935-9BA2-96BEB123870CQ40647458-0AA31927-A3E4-42FC-AD43-4B8FF0EAE51AQ40865994-4DE9B7E9-5A28-4C02-B0F1-0925153390BCQ40890875-72899DDD-6450-4588-99C4-93BE9AA70EECQ42536982-1F561683-07EF-445A-A8E7-8194497B3785Q43558328-9D4F878A-C7BF-4AA0-926A-64691E80A5D7Q44087754-7E1C4E82-8B94-4137-B61E-336594165949Q45984305-6350A5F4-9EEF-4E5E-A7EB-146EAFE988DAQ48967021-1035F8BF-852C-4004-A36A-A3D62855C8B7Q53841482-247CA65B-EF08-4DBC-8B86-250D308F3DE9Q54077157-39A34F15-16AF-4044-BF05-0FC3B72F0D1CQ57142375-4D502347-E9BE-4042-8123-6FE5770D4B8B
P2860
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Paclitaxel and recombinant hum ...... for metastatic breast cancer.
@en
type
label
Paclitaxel and recombinant hum ...... for metastatic breast cancer.
@en
prefLabel
Paclitaxel and recombinant hum ...... for metastatic breast cancer.
@en
P2093
P1476
Paclitaxel and recombinant hum ...... for metastatic breast cancer.
@en
P2093
A D Seidman
B S Reichman
D E Lebwohl
T A Gilewski
P304
P356
10.1200/JCO.1993.11.10.1943
P407
P577
1993-10-01T00:00:00Z